Paediatric steatotic liver disease has unique characteristics: A multisociety statement endorsing the new nomenclature

Nonalcoholic fatty liver disease (NAFLD) has been a commonly used term and diagnosis in paediatric hepatology, gastroenterology, and endocrinology clinics for over 30 years. A multisociety Delphi process has determined a new name “Steatotic Liver Disease” (SLD) as the overarching term for disorders associated with hepatic lipid accumulation. Our Societies give our support to steatotic liver disease as the best overarching term for use in our communities. Metabolic dysfunction‐associated steatotic liver disease (MASLD) overcomes many of the shortcomings of the name NAFLD. Here, we highlight several points of the new nomenclature that are of particular importance for our community and their consequences for implementation including: diagnostic criteria, considering alternate diagnoses, practical implementation, research, advocacy, and education for paediatricians. As with all nomenclature changes, it will take a concerted effort from our paediatric societies to help integrate the optimal use of this into practice. What is Known “Metabolic dysfunction associated steatotic liver disease” (MASLD) is the new name for “Nonalcoholic fatty liver disease.” Other liver diseases may masquerade as paediatric MASLD. What is New Globally, paediatric societies endorse the use of MASLD. The diagnostic pathway for paediatric MASLD differs to that of adult MASLD. Ongoing education & training is need for all stakeholders to implement the use of MASLD.